January 16, 2017, Stockholm: Redwood Pharma AB (publ) has now according to plan completed optimization work surrounding the manufacturing process of RP101 that is needed for the coming safety studies. RP101 represents the combination of the company’s active substance and the IntelliGel® drug delivery platform. Production of RP101 for the safety studies will now begin.
IntelliGel® is a drug delivery system that controls the release of an active substance in a pharmaceutical drug. IntelliGel® can be combined with a variety of different substances and is an attractive method for the formulation of new pharmaceutical drugs, as well as the reformulation of established medicines to improve therapeutic effect and safety. As the work surrounding production of the company’s first pharmaceutical drug candidate is completed, an important milestone surrounding the development work surrounding RP101 – the company’s pharmaceutical drug candidate to treat chronic dry eye in women – has been achieved. The established manufacturing process has significance as to how IntelliGel can be used in combination with other active pharmaceutical ingredients.
“We are now entering an active and exciting period in the company. I’m very satisfied that we are delivering results according to plan. 2017 will be a very important year for us as we will complete our toxicology studies and start Phase II clinical trial of RP101. We can now realize our technological and commercial advantages of our company’s assets. With an innovative drug delivery system and Phase II data regarding a widely-accepted active substance, we are confident about the future”, says CEO Martin Vidaeus.
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
This information is information that Redwood Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at January 16, 2017.
About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel®, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.
Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information visit: www.redwoodpharma.com